US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Veraxa Biotech Holding AG

1.35

-0.0900-6.25%

Pre-market: 1.390.0400+2.96%08:26 EDT

Volume:315.75K

Turnover:430.98K

Market Cap:190.90M

PE:6.30

High:1.45

Open:1.43

Low:1.32

Close:1.44

52wk High:27.36

52wk Low:1.32

Shares:141.41M

Float Shares:41.01M

Volume Ratio:1.09

T/O Rate:0.77%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.2142

EPS(LYR):-5.8037

ROE:-871.42%

ROA:-49.99%

PB:-9.79

PE(LYR):-0.23

Loading ...

Overview Company News Filings

VERAXA Biotech (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany

Veraxa Biotech Names Christoph Erkel Chief Scientific Officer, Succeeding Rick Austin

Veraxa Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance Bitac® Technology Platforms and Portfolio

THOMSON REUTERS

Veraxa Biotech Receives PEI Scientific Advice on Bitac-tce Development Plan

Veraxa Biotech Announces Regulatory Progress with Its Bitac®-tce Development Plan

THOMSON REUTERS

VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan

Why VERAXA Biotech (NASDAQ: VRXA) Could Benefit More Than Others From AI’s Growing Impact on Drug R&D

Veraxa Collaborates With Ardigen to Use AI for Cancer Drug Development

MT Newswires Live

Veraxa Biotech to Launch Ai-enabled Drug Discovery Collaboration with Ardigen to Support Growing Bitac® Pipeline

THOMSON REUTERS

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

FB Financial, Smith Micro Software And 3 Stocks To Watch Heading Into Monday

Benzinga Earnings

Veraxa Biotech Names Carl Von Halem Interim CFO, Replacing Torsten Bürgermeister

Veraxa CFO Torsten Burgermeister steps down, Carl von Halem named interim CFO

Veraxa Biotech Ag Appoints Carl Von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister

THOMSON REUTERS

VERAXA Biotech (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership

VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition

Veraxa Biotech Proposes Raising Conditional Capital Ceiling to CHF 459,789 Via Bylaw Change

VERAXA Biotech (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy

Veraxa Biotech provides pipeline and partnering strategy update

Veraxa Biotech Ag - Targets Vxa-102 Ind/cta-ready by Beginning of 2028

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/VRXA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VRXA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","market":"US","secType":"STK","nameCN":"Veraxa Biotech Holding AG","latestPrice":1.35,"timestamp":1787947200000,"preClose":1.44,"halted":0,"volume":315752,"hourTrading":{"tag":"盘前","latestPrice":1.39,"preClose":1.35,"latestTime":"08:26 EDT","volume":584,"amount":809.9999992,"timestamp":1788179194979,"change":0.04,"changeRate":0.02963,"amplitude":0.02963},"delay":0,"changeRate":-0.0624999999999999,"floatShares":41012504,"shares":141407813,"eps":0.2142,"marketStatus":"Pre-Mkt","change":-0.09,"latestTime":"08-31 09:24:52 EDT","open":1.43,"high":1.45,"low":1.32,"amount":430979.850988,"amplitude":0.090278,"askPrice":1.67,"askSize":1500,"bidPrice":1.3,"bidSize":50,"shortable":3,"etf":0,"ttmEps":0.2142,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788183000000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":1.35,"preHourTrading":{"tag":"盘前","latestPrice":1.39,"preClose":1.35,"latestTime":"08:26 EDT","volume":584,"amount":809.9999992,"timestamp":1788179194979,"change":0.04,"changeRate":0.02963,"amplitude":0.02963},"postHourTrading":{"tag":"盘后","latestPrice":1.3685,"preClose":1.35,"latestTime":"19:55 EDT","volume":6489,"amount":8801.0691,"timestamp":1787961331465,"change":0.0185,"changeRate":0.013704,"amplitude":0.013704},"volumeRatio":1.0891754061145933},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","floatShares":41012504,"roa":"-49.99%","roe":"-871.42%","lyrEps":-5.803658,"volumeRatio":1.0891754061145933,"shares":141407813,"dividePrice":0,"high":1.45,"amplitude":0.090278,"preClose":1.44,"low":1.32,"week52Low":1.32,"pbRate":"-9.79","psRate":"6587.79","week52High":27.36,"institutionHeld":0,"latestPrice":1.35,"committee":-0.935484,"eps":0.2142,"divideRate":0,"volume":315752,"delay":0,"ttmEps":0.2142,"open":1.43,"prevYearClose":18.65,"prevWeekClose":1.35,"prevMonthClose":1.76,"prevQuarterClose":1.88,"fiveDayClose":1.95,"twentyDayClose":1.76},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VRXA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VRXA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VRXA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/VRXA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"VRXA","date":"2026-08-28","current":6.302521,"percent":1,"low":-1.401348,"twenty":-1.349054,"median":-1.281094,"eighty":-1.194963,"high":-1.03732,"avg":-1.262232,"sd":0.113484,"marketCap":36312933},"quantilePoints":[{"date":"2026-08-21","current":-1.35335,"twenty":-1.349054,"median":-1.34261,"eighty":-1.336165,"marketCap":47660725},{"date":"2026-08-28","current":-1.03732,"twenty":-1.349054,"median":-1.281094,"eighty":-1.194963,"marketCap":36312933}],"updateTime":1788182692357},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VRXA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2653017724","title":"VERAXA Biotech (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany","url":"https://stock-news.laohu8.com/highlight/detail?id=2653017724","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653017724?lang=en_us&edition=fundamental","pubTime":"2026-07-24 00:30","pubTimestamp":1784824207,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, July 23rd, 2026, FinanceWire The company has received Scientific Advice from Germany’s Paul-Ehrlich-Institute (...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-bitacr-tce-development-with-positive-regulatory-feedback-from-germany?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-bitacr-tce-development-with-positive-regulatory-feedback-from-germany?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QQQ","FTEC","QDTE","BK4581","NVIW.SI","QQQY","BK4022","QLD","QQQA","SQQQ","GPIQ","QID","VRXA","PSQ","QQQJ","R","BK4585","NDX","XBI","BK4232","TQQQ","BK4588","JEPQ",".IXIC","ONEQ","IYW","QQQM","TQQY","MNQmain","QYLG","QQQE","BK4139","TECS","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653774107","title":"Veraxa Biotech Names Christoph Erkel Chief Scientific Officer, Succeeding Rick Austin","url":"https://stock-news.laohu8.com/highlight/detail?id=2653774107","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653774107?lang=en_us&edition=fundamental","pubTime":"2026-07-23 19:02","pubTimestamp":1784804567,"startTime":"0","endTime":"0","summary":"Veraxa Biotech names Christoph Erkel chief scientific officer, succeeding Rick AustinVeraxa Biotech named Christoph Erkel chief scientific officer, effective immediately, to drive development of its B","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL6Sv8GL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","VRXA","SG9999014013.SGD","BCDF","NDAQ","LU0314104364.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014039.USD","IE00BN0W2T93.GBP","LU2095319765.USD","LU2210150020.SGD","IE00BN0W2W23.USD","BK4112","IE00BN0W2V16.EUR","SG9999014005.SGD","BK4585","BK4588","BK4139","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653741470","title":"Veraxa Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance Bitac® Technology Platforms and Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2653741470","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653741470?lang=en_us&edition=fundamental","pubTime":"2026-07-23 19:00","pubTimestamp":1784804401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nTUA9W6BWL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652297746","title":"Veraxa Biotech Receives PEI Scientific Advice on Bitac-tce Development Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2652297746","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652297746?lang=en_us&edition=fundamental","pubTime":"2026-07-20 19:01","pubTimestamp":1784545318,"startTime":"0","endTime":"0","summary":"Veraxa Biotech receives PEI scientific advice on BiTAC-TCE development planVeraxa Biotech received Scientific Advice from Germany’s Paul-Ehrlich-Institute on the biology and non-clinical development p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDL9D96jD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","IE00BKPKM429.USD","SG9999014039.USD","LU2095319765.USD","IE00BN0W2W23.USD","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","LU0314104364.USD","BK4585","LU2210150020.SGD","SG9999014021.USD","VRXA","SG9999014013.SGD","NDAQ","BCDF","IE00BN0W2T93.GBP","BK4112","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652297476","title":"Veraxa Biotech Announces Regulatory Progress with Its Bitac®-tce Development Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2652297476","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652297476?lang=en_us&edition=fundamental","pubTime":"2026-07-20 19:00","pubTimestamp":1784545200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nTUABZVG5Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652297045","title":"VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2652297045","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652297045?lang=en_us&edition=fundamental","pubTime":"2026-07-20 19:00","pubTimestamp":1784545200,"startTime":"0","endTime":"0","summary":"Scientific Advice from the German Regulatory Authority supports the biological rationale and proposed development approach for VERAXA's BiTAC-TCE technology and product candidate, providing an initial","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/20/3329623/0/en/VERAXA-Biotech-Announces-Regulatory-Progress-with-its-BiTAC-TCE-Development-Plan.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4097","BK4139","VRXA","XBI","BK4581","PRGS","LU2065732104.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651460997","title":"Why VERAXA Biotech (NASDAQ: VRXA) Could Benefit More Than Others From AI’s Growing Impact on Drug R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=2651460997","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651460997?lang=en_us&edition=fundamental","pubTime":"2026-07-16 01:30","pubTimestamp":1784136642,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, July 15th, 2026, FinanceWire Artificial intelligence is becoming an increasingly important tool for drug discovery, w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/why-veraxa-biotech-nasdaq-vrxa-could-benefit-more-than-others-from-ais-growing-impact-on-drug-rd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/why-veraxa-biotech-nasdaq-vrxa-could-benefit-more-than-others-from-ais-growing-impact-on-drug-rd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSQ","VRXA","QDTE","ARTY","QLD","XBI","TECS","SQQQ","TQQY","TQQQ","QQQE","QQQY","QID","BK4585","QQQA","NVIW.SI","BK4588","CHAT","NQmain","VTHR","QQQ","GPIQ","MNQmain","AGIX","FTEC","JEPQ","NDX","ONEQ","AIPO","BK4139","QQQJ","BK4581","QYLG","QQQM","QTOC","IYW",".IXIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651023119","title":"Veraxa Collaborates With Ardigen to Use AI for Cancer Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2651023119","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651023119?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:14","pubTimestamp":1783944865,"startTime":"0","endTime":"0","summary":"Veraxa Biotech  said Monday it is collaborating with Ardigen to use artificial intelligence to advance its BiTAC cancer therapy pipeline.The partnership will initially focus on developing AI tools to identify and prioritize dual-target combinations for Veraxa's bispecific T-cell engagers and antibody-drug conjugates, it said.The company said its BiTAC platform uses an \"AND-gate\" approach that activates when two cancer targets are present on the same cell, a strategy designed to reduce off-target toxicity and improve treatment precision.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AIPO","ARTY","AGIX","VRXA","BK4139","VTHR","QTOC","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651115682","title":"Veraxa Biotech to Launch Ai-enabled Drug Discovery Collaboration with Ardigen to Support Growing Bitac® Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2651115682","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651115682?lang=en_us&edition=fundamental","pubTime":"2026-07-13 19:00","pubTimestamp":1783940400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUA89CKY9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651115444","title":"VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2651115444","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651115444?lang=en_us&edition=fundamental","pubTime":"2026-07-13 19:00","pubTimestamp":1783940400,"startTime":"0","endTime":"0","summary":"Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs)ZURICH, SWITZERL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/13/3326056/0/en/VERAXA-Biotech-to-Launch-AI-enabled-Drug-Discovery-Collaboration-with-Ardigen-to-Support-Growing-BiTAC-Pipeline.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIX","CHAT","VTHR","ARTY","AIPO","XBI","VRXA","BK4581","QTOC","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651819687","title":"FB Financial, Smith Micro Software And 3 Stocks To Watch Heading Into Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2651819687","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651819687?lang=en_us&edition=fundamental","pubTime":"2026-07-13 14:35","pubTimestamp":1783924558,"startTime":"0","endTime":"0","summary":"U.S. stock futures down today, FB Financial, Smith Micro Software, LogProstyle, Veraxa Biotech, and Q32 Bio among stocks to watch. More premarket coverage at Benzinga.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/07/60406840/fb-financial-smith-micro-software-and-3-stocks-to-watch-heading-into-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4023","BK4024","SMSI","LGPS","VRXA","FBK","QTTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650137343","title":"Veraxa Biotech Names Carl Von Halem Interim CFO, Replacing Torsten Bürgermeister","url":"https://stock-news.laohu8.com/highlight/detail?id=2650137343","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650137343?lang=en_us&edition=fundamental","pubTime":"2026-07-11 04:22","pubTimestamp":1783714941,"startTime":"0","endTime":"0","summary":"Veraxa Biotech names Carl von Halem interim CFO, replacing Torsten BürgermeisterVeraxa appointed Carl von Halem as interim chief financial officer, replacing Torsten Bürgermeister.Management is in lat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nNDL7g0x3j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650137360","title":"Veraxa CFO Torsten Burgermeister steps down, Carl von Halem named interim CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2650137360","media":"TIPRANKS","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650137360?lang=en_us&edition=fundamental","pubTime":"2026-07-11 04:10","pubTimestamp":1783714212,"startTime":"0","endTime":"0","summary":"Veraxa Biotech (VRXA) announced the appointment of Carl von Halem as interim CFO. He succeeds Torsten Burgermeister. The company is currently in th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veraxa-cfo-torsten-burgermeister-steps-down-carl-von-halem-named-interim-cfo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veraxa-cfo-torsten-burgermeister-steps-down-carl-von-halem-named-interim-cfo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4581","BK4139","XBI","VRXA","BK4585","CFO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650132783","title":"Veraxa Biotech Ag Appoints Carl Von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister","url":"https://stock-news.laohu8.com/highlight/detail?id=2650132783","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650132783?lang=en_us&edition=fundamental","pubTime":"2026-07-11 04:05","pubTimestamp":1783713900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nTUA8QNSV0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650975096","title":"VERAXA Biotech (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2650975096","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650975096?lang=en_us&edition=fundamental","pubTime":"2026-07-10 01:00","pubTimestamp":1783616408,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, July 9th, 2026, FinanceWire The company has initiated cell line development for its lead BiTAC(R) T-cell engager prog...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-lead-bitacr-t-cell-engager-program-with-cell-line-development-partnership?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-lead-bitacr-t-cell-engager-program-with-cell-line-development-partnership?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSQ","GPIQ","BK4232","QQQ","R","IYW","QQQJ","TQQQ","SQQQ","BK4585","QQQA","BK4139","MNQmain","QYLG","TQQY","QQQE","ONEQ","QQQY","NQmain","QQQM","QDTE","BK4581","DBB","BK4588","BK4022",".IXIC","JEPQ","NVIW.SI","FTEC","QLD","XBI","NDX","TECS","QID","VRXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649931305","title":"VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2649931305","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649931305?lang=en_us&edition=fundamental","pubTime":"2026-07-08 00:30","pubTimestamp":1783441807,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, July 7th, 2026, FinanceWire Novartis has agreed to acquire Myricx Bio for $1.1 billion upfro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-shareholders-should-watch-novartis-latest-1-5b-adc-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-shareholders-should-watch-novartis-latest-1-5b-adc-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QLD","NETL","QQQJ","MNQmain","BK4231","PSQ","IYW","QDTE","QID","BK4139","NVIW.SI","QYLG","TQQY","VRXA","TECS","NDX","TQQQ","NQmain","QQQE","QQQ","JEPQ","QQQA","BK4581","QQQY","ONEQ","BK4080","GPIQ","ADC","QQQM","BK4585","FTEC","SQQQ","XBI","BK4588",".IXIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649291679","title":"Veraxa Biotech Proposes Raising Conditional Capital Ceiling to CHF 459,789 Via Bylaw Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2649291679","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649291679?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:11","pubTimestamp":1783368675,"startTime":"0","endTime":"0","summary":"Veraxa Biotech proposes raising conditional capital ceiling to CHF 459,789 via bylaw changeVeraxa Biotech set a July 24, 2026 extraordinary shareholder vote on bylaw changes expanding its equity issua","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDLblPcHf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649753526","title":"VERAXA Biotech (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2649753526","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649753526?lang=en_us&edition=fundamental","pubTime":"2026-07-07 01:00","pubTimestamp":1783357208,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, July 6th, 2026, FinanceWire VERAXA Biotech (NASDAQ:VRXA) provided a corporate and pipeline update highlighting p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-highlights-bitac-pipeline-progress-advances-partnering-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-highlights-bitac-pipeline-progress-advances-partnering-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TQQY","TECS","BK4097","NVIW.SI","QQQM","FTEC",".IXIC","QLD","IYW","QQQ","SQQQ","QQQJ","NQmain","XBI","BK4581","QQQA","LU2065732104.USD","GPIQ","BK4585","BK4139","PRGS","QDTE","BK4588","VRXA","PSQ","QID","QQQY","QYLG","TQQQ","NDX","JEPQ","QQQE","MNQmain","ONEQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649242006","title":"Veraxa Biotech provides pipeline and partnering strategy update","url":"https://stock-news.laohu8.com/highlight/detail?id=2649242006","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649242006?lang=en_us&edition=fundamental","pubTime":"2026-07-06 21:15","pubTimestamp":1783343707,"startTime":"0","endTime":"0","summary":"Veraxa Biotech (VRXA) provided a company and pipeline update, highlighting its strategic focus on its proprietary BiTAC platform. The company inten...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veraxa-biotech-provides-pipeline-and-partnering-strategy-update-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veraxa-biotech-provides-pipeline-and-partnering-strategy-update-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","XBI","BK4581","VRXA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649625646","title":"Veraxa Biotech Ag - Targets Vxa-102 Ind/cta-ready by Beginning of 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2649625646","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649625646?lang=en_us&edition=fundamental","pubTime":"2026-07-06 19:00","pubTimestamp":1783335602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nTUA5CXFFC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":68,"code":"91000000","status":"200"}]}}